Overview of the safety, efficiency, and potential mechanisms of finerenone for diabetic kidney diseases.

Front Endocrinol (Lausanne) · 2023 · PMC10762446 · PMID 38174337

Europe PMC DOI

hedged sentence

0.0690

closest p · 1.4× alpha

0.0690

boldest claim

The sentences

did not reach statistical significanceP = 0.069so close (0.05 < p ≤ 0.1)

While a lower incidence rate for the eGFR ≥40% kidney composite endpoint was noted with FIN compared to placebo, it did not reach statistical significance (P = 0.069).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.